MedPath

Study on Sit to Quit Phone Intervention

Not Applicable
Completed
Conditions
Nicotine Dependence
Interventions
Behavioral: Quit for Life
Behavioral: Sit to Quit
Registration Number
NCT02840435
Lead Sponsor
Duke University
Brief Summary

This study is designed to test the effectiveness of the smoking cessation intervention "Sit to Quit" through a randomized-control trial. This study will compare abstinence outcomes in the Sit to Quit study group to a control group using the North Carolina State Tobacco Quit Line.

Detailed Description

This study is designed to test the effectiveness of the smoking cessation intervention "Sit to Quit" through a randomized-control trial. This study will compare abstinence outcomes in the Sit to Quit study group to a control group using the North Carolina State Tobacco Quit Line. This is an investigational study (n=60) designed to test Sit to Quit (STQ) versus Quit Line (QL) through a pilot randomized control trial. The proposed study is designed with double-blind procedures (participants and study staff) for randomization of 60 participants recruited through Duke Smoking Cessation Program into two groups: STQ and QL. STQ participants will receive access to the STQ Instructional Video, the STQ manual, and proactive Quit Coach calls supporting STQ. QL participants will be instructed to contact the NC Quit Line and will receive access to "web Coach" (Alere Well-being site), the Quit Line manual, and proactive Quit Coach calls supporting "Quit for Life." All statistical analysis will be performed under the directions of the statistician designated in key personnel. Outcomes of variables including: demographic variables, evaluation responses, and abstinence rates will be analyzed using general regression models using an ANOVA-based design. The study Principal Investigator Dr. James Davis will ultimately be responsible for data and safety monitoring. Subject data will be collected during visits and captured in the Electronic Medical Record. Data will be collected by phone, and this data will be stored in REDCap. Participants that experience events related to their clinical treatment will be recommended to follow-up with their provider.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
23
Inclusion Criteria
  • Patient being treated at Duke Smoking Cessation Program for tobacco use
  • Age 18 years or older
  • Actively smoking 5 or more cigarettes per day for at least one year
  • Fluency in spoken and written English
  • Willing to set a quit date within 2 weeks
  • Access to a smart phone or internet and telephone
  • Willingness to watch 3 videos on computer, receive 5 counseling calls, and attend investigational visits.
Exclusion Criteria
  • CO test under 7 ppm during initial screening
  • 8 or above on the Alcohol Use Disorders Identification Test (AUDIT-10)
  • 6 or above on Drug Abuse Screening Test (DAST-10)
  • 3 or above on Patient Health Questionnaire (PHQ-2) Depression Scale
  • Daily use of a second form of tobacco or nicotine (e.g. e-cigarettes, cigars, chewing tobacco, snuff)
  • Current use of a smoking cessation medication (e.g. nicotine replacement, Varenicline, Bupropion)
  • Intolerable side effects related to, refusal to take, or medical contraindication with nicotine patch
  • Symptomatic cognitive or emotive disorder such as untreated schizophrenia, severe untreated depression, or severe untreated anxiety. This is determined by clinical assessment.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
North Carolina Quit Line: Quit for LifeQuit for LifeParticipants will be connected to the 'Quit for Life' program offered through the North Carolina Quit Line.
Sit to QuitSit to QuitParticipants will be connected to the 'Sit to Quit' program offered through the Duke Smoking Cessation Program.
Primary Outcome Measures
NameTimeMethod
Biochemically confirmed continuous 30-day abstinence from smoking12 weeks post-Target Quit Day (TQD)

Biochemically confirmed 30-day continuous abstinence. Abstinence is determined by a participant both reporting not smoking in the past 30 days AND a result of \< 7 ppm in carbon monoxide breath testing. If the participant does not meet both criteria, they are not considered abstinent

Secondary Outcome Measures
NameTimeMethod
Changes in anxietyBaseline to 2-week and 12-week post TQD

Change in self-reported measures of anxiety

Changes in depressionBaseline to 2-week and 12-week post TQD

Change in self-reported measures of depression

Biochemically confirmed 7-day point prevalence abstinence from smoking2 weeks post-TQD

Biochemically confirmed 7-day continuous abstinence. Abstinence is determined by a participant both reporting not smoking in the past 7 days AND a result of \< 7 ppm in carbon monoxide breath testing. If the participant does not meet both criteria, they are not considered abstinent

Self-reported 7-day point prevalence abstinence rates2 weeks post TQD

7-day point prevalence abstinence as measured by phone-based, single-item self-report

Smoking reduction26 weeks post-TQD

Smoking reduction as measured by number of cpd measured by phone-based self-report

Changes in stressBaseline to 2-week and 12-week post TQD

Change in self-reported measures of stress

Changes in relapse predictorsBaseline to 1-week post-TQD, 2-week post-TQD, 6-week post-TQD, 12-week post-TQD, and 26-week post-TQD

Changes in self-reported measures on repeated non-standardized single-item question on stress, urges, and confidence assessed by phone

Feasibility: mindfulness practices1-week post-TQD, 2-week post-TQD, 6-week post-TQD, and 26-week post-TQD

Feasibility as measured by non-standardized phone-based self-report of number of times mindfulness practices are used by experimental group

Feasibility: meditation time1-week post-TQD, 2-week post-TQD, 6-week post-TQD, and 26-week post-TQD

Feasibility as measured by non-standardized phone-based self-report of time spent meditating by experimental group

Feasibility: attendance recordsUp to 12 weeks post-TQD

Feasibility as measured by attendance and completion of STQ and QL assessed by attendance records taken instructors during phone sessions.

Feasibility: website usageUp to 12 weeks post-TQD

Feasibility as measured by website usage by electronically recording login and using a site-based timer to record time accessing the site through each intervention

Feasibility: course evaluationUp to 12 weeks post-TQD

Feasibility as measured by course evaluation

Feasibility: demographics12-weeks post-TQD

Feasibility as measured by demographics of patients at DSCP

Feasibility: Behavioral intervention used12 weeks post-TQD

Feasibility as measured by behavioral intervention assignment

Feasibility: Attendance at DSCP appointments12 weeks post-TQD

Feasibility as measured by attendance at DSCP appointments

Feasibility: Referral routes to DSCPBaseline

Feasibility as measured by referral routes to DSCP

Feasibility: Side effects1-week post-TQD, 2-week post-TQD, and 6-week post-TQD

Feasibility as measured by side effects, as measured by phone assessment

Feasibility: medication adherence1-week post-TQD, 2-week post-TQD, 6-week post-TQD, and 26-week post-TQD

Feasibility as measured by medication adherence, as measured by phone assessment

Trial Locations

Locations (1)

Duke Center for Smoking Cessation

🇺🇸

Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath